Effect of diets on lipoprotein concentrations in heterozygous apolipoprotein E-deficient mice

被引:8
作者
Bobková, D
Honsová, E
Kovár, J
Poledne, R
机构
[1] Inst Clin & Expt Med, Lab Atherosclerosis Res, Videnska 1058-9, Prague 14021 4, Czech Republic
[2] Ctr Expt Cardiovasc Res, Prague, Czech Republic
[3] Inst Clin & Expt Med, Dept Anat & Pathol, Prague, Czech Republic
关键词
apolipoprotein E; heterozygous mice; hyperlipoproteinemia; hepatotoxicity;
D O I
10.33549/physiolres.930475
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Loss of apolipoprotein E synthesis causes increased serum cholesterol concentrations and the sensitivity to high-fat diet in mice. We analyzed the changes in lipoprotein and hepatic structures in apolipoprotein E-deficient mice kept on control diet and cholesterol diets. Basal cholesterolemia of heterozygous (+/-) mice (2.2+/-0.28 mmol/l) was the same compared to wild-type (+/+) mice (2.3+/-0.15 mmol/l), but was lower compared to homozygous (-/-) mice (10.3+/-1.40 mmol/l). In +/- mice, cholesterolemia rose to 3.2 mmol/l on cholesterol diet and to 9 mmol/l on cholate diet, to 3 mmol/l and 3.6 mmol/l in +/+ mice, and to 23.4 mmol/l and 70.5 mmol/l in -/- mice. respectively. While the ratio of cholesterol/triglyceride concentrations in VLDL, IDL and LDL fractions was not increased in mice and mice, it was increased in -/- mice on control diet. On the cholesterol diet, this ratio rose and was dramatically increased by cholate diet in all groups of mice. Even though cholate supplementation increased cholesterol concentration, it led to substantial toxic changes in hepatic morphology of all animals. In conclusion, one functional apo E allele in +/- mice is effective in keeping serum cholesterol concentrations in normal range on a control diet, but not on the cholesterol and cholate diets.
引用
收藏
页码:635 / 643
页数:9
相关论文
共 21 条
[1]   THE LDL RECEPTOR RELATED PROTEIN, LRP, IS AN APOLIPOPROTEIN-E-BINDING PROTEIN [J].
BEISIEGEL, U ;
WEBER, W ;
IHRKE, G ;
HERZ, J ;
STANLEY, KK .
NATURE, 1989, 341 (6238) :162-164
[2]  
BOBKOVA D, 2002, PHYSIOL RES, V51, pP65
[3]   TRANSGENIC MOUSE MODELS OF LIPOPROTEIN METABOLISM AND ATHEROSCLEROSIS [J].
BRESLOW, JL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8314-8318
[4]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[5]   TYPE-III HYPERLIPOPROTEINEMIA - DIAGNOSIS, MOLECULAR DEFECTS, PATHOLOGY, AND TREATMENT [J].
BREWER, HB ;
ZECH, LA ;
GREGG, RE ;
SCHWARTZ, D ;
SCHAEFER, EJ .
ANNALS OF INTERNAL MEDICINE, 1983, 98 (05) :623-640
[6]  
DESILVA HV, 1994, J LIPID RES, V35, P1297
[7]  
GOTTO AM, 1986, METHOD ENZYMOL, V128, P3
[8]   Treatment of type III hyperlipoproteinemia [J].
Guyton, JR .
AMERICAN HEART JOURNAL, 1999, 138 (01) :17-18
[9]   DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM [J].
HAVEL, RJ ;
EDER, HA ;
BRAGDON, JH .
JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) :1345-1353
[10]  
Innis-Whitehouse W, 1998, J LIPID RES, V39, P679